Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin’s lymphoma
Author:
Open Access
- 1 October 2009
- journal article
- review article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. 1, 131-6
Abstract
Peer reviewed article authored by (Christos Emmanouilides). Read article or submit your manuscript for publishing.Keywords
This publication has 28 references indexed in Scilit:
- Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma.2008
- A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patientsAnnals of Oncology, 2008
- A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium‐90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non‐Hodgkin lymphomaCancer, 2008
- How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies?Leukemia & Lymphoma, 2008
- Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan RadioimmunotherapyJournal of Clinical Oncology, 2007
- Radioimmunotherapy for Non-Hodgkin Lymphoma : Historical Perspective and Current StatusJournal of Clinical and Experimental Hematopathology, 2007
- Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular LymphomaJournal of Clinical Oncology, 2005
- Antilymphoma Treatments Given Subsequent to Yttrium 90 Ibritumomab Tiuxetan Are Feasible in Patients with Progressive Non-Hodgkin's Lymphoma: A Review of the LiteratureClinical Lymphoma, 2004
- Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.2003
- Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002